

SUBJECT INDEX TO VOLUME 2

<p>Acridones64</p> <p style="padding-left: 20px;">chemistry of64</p> <p style="padding-left: 20px;">effect of derivatives on cellular accumulation/ efflux of [³H]VLB65</p> <p style="padding-left: 20px;">in drug-sensitive/resistant cancer cell lines69</p> <p style="padding-left: 20px;"><i>in vitro</i> cytotoxicity of69</p> <p style="padding-left: 20px;">lipophilicity effects of65</p> <p style="padding-left: 20px;">pharmacological activity of65</p> <p>Akt-dependent cross-talk2</p> <p>Aldose reductase inhibitors39</p> <p style="padding-left: 20px;">chemistry of41</p> <p style="padding-left: 20px;">thienocinnolinone alkanolic acid derivatives as39</p> <p>Alkylating steroidal esters569</p> <p style="padding-left: 20px;"><i>in vitro</i> evaluation of569</p> <p style="padding-left: 20px;">rational design of569</p> <p style="padding-left: 20px;">synthesis of569</p> <p>All-<i>trans</i>-retinoic acid457</p> <p style="padding-left: 20px;">alkaline phosphatase activity in pancreatic cancer cells457</p> <p style="padding-left: 20px;">effect on cell cycle457</p> <p style="padding-left: 20px;">flow cytometric analysis of457</p> <p style="padding-left: 20px;">MTT assay of457</p> <p>2-Amino-1,4-benzoquinones591</p> <p style="padding-left: 20px;">anti-neoplastic effects of591</p> <p style="padding-left: 20px;">inhibition of human 5-lipoxygenase by591</p> <p>5-(4-Aminophenyl)-4-substituted-2,4-dihydro-3h-1,2,4- triazole-3-thione derivatives415</p> <p style="padding-left: 20px;">antituberculosis activity relationships study of415</p> <p style="padding-left: 20px;">electronic-topological/neural networks approach to415</p> <p style="padding-left: 20px;">structure of415</p> <p>4-Androstene-3,17-dione/adenosine hybrid compounds329</p> <p style="padding-left: 20px;">as bisubstrate inhibitors of type 317β- hydroxysteroid dehydrogenase329</p> <p style="padding-left: 20px;">chemical synthesis of331</p> <p style="padding-left: 20px;">design of329</p> <p style="padding-left: 20px;"><i>in vitro</i> evaluation of329</p> <p style="padding-left: 20px;">inhibition of334</p> <p style="padding-left: 20px;">synthesis of329</p> <p>Anticancer activity597</p> <p style="padding-left: 20px;">of 5-benzylidene-2-phenylimino-1,3-thiazolidin- 4-one (BPT) analogs597</p> <p>Anticancer drugs113</p> <p style="padding-left: 20px;">in multi-drug resistant cell lines113</p> <p>Anticonvulsant arylsemicarbazones55</p> <p style="padding-left: 20px;">chemistry of55</p> <p style="padding-left: 20px;">pharmacological activity of55</p> <p style="padding-left: 20px;">structure-activity relationship of55,60</p> <p style="padding-left: 20px;">synthesis of55</p> <p>Antisense14</p> <p style="padding-left: 20px;">modification of14</p> <p style="padding-left: 20px;">principle of14</p>	<p>Apoptosis1</p> <p style="padding-left: 20px;">apoptogenic factors in5</p> <p style="padding-left: 20px;">BAD pathway in2</p> <p style="padding-left: 20px;">BAP 31 in6</p> <p style="padding-left: 20px;">Bcl-2 family in6,8</p> <p style="padding-left: 20px;">BI-1 in7</p> <p style="padding-left: 20px;">c-Abl in8</p> <p style="padding-left: 20px;">caspases in3</p> <p style="padding-left: 20px;">c-Jun N-terminal kinase JNK in3</p> <p style="padding-left: 20px;">cytochrome in4</p> <p style="padding-left: 20px;">endo G in5</p> <p style="padding-left: 20px;">hexokinases in3</p> <p style="padding-left: 20px;">IP3R in5</p> <p style="padding-left: 20px;">NF-κB in5</p> <p style="padding-left: 20px;">NF-κB/IκB in5,9</p> <p style="padding-left: 20px;">non-kinase-dependent pathways in3</p> <p style="padding-left: 20px;">p53 family proteins in4,9</p> <p style="padding-left: 20px;">PACS-2 in7</p> <p style="padding-left: 20px;">protein kinase C in3</p> <p style="padding-left: 20px;">therapeutic targets for7</p> <p>Apoptosis inducing factor (AIF)5</p> <p>Apoptosis signal-regulating kinase 1 (ASK 1)3</p> <p>2'-Arabinofluoro-2'-deoxyuridine analogues287</p> <p style="padding-left: 20px;">biological studies of287</p> <p style="padding-left: 20px;">chemistry of288</p> <p style="padding-left: 20px;"><i>in vitro</i> anti-mycobacterial activities of287</p> <p style="padding-left: 20px;">synthesis of287</p> <p>2'-Arabinouridine287</p> <p style="padding-left: 20px;">biological studies of287</p> <p style="padding-left: 20px;">chemistry of288</p> <p style="padding-left: 20px;"><i>in vitro</i> anti-mycobacterial activities of287</p> <p style="padding-left: 20px;">synthesis of287</p> <p>Arterial proliferative diseases13</p> <p style="padding-left: 20px;">antisense treatment for14</p> <p style="padding-left: 20px;">mechanisms of13</p> <p style="padding-left: 20px;">ribozyme treatments for15</p> <p>Aryl-acetic251</p> <p style="padding-left: 20px;">anti-inflammatory activity of251</p> <p style="padding-left: 20px;">as antioxidant251</p> <p style="padding-left: 20px;">as novel lipoxygenase inhibitors251</p> <p style="padding-left: 20px;">chemistry of252</p> <p style="padding-left: 20px;">physicochemical studies of254</p> <p style="padding-left: 20px;">synthetic methodology for252</p> <p>ATP/non-ATP dependent inhibitors213</p> <p style="padding-left: 20px;">development of213</p> <p style="padding-left: 20px;">docking domains on218</p> <p style="padding-left: 20px;">inhibition based on disrupting protein-protein interactions218</p> <p>Benzophenones377</p> <p style="padding-left: 20px;">cytoprotective effects of377</p> <p style="padding-left: 20px;">from <i>Hypericum annulatum</i> in models of epirubicin-induced cytotoxicity377</p> <p style="padding-left: 20px;">mechanistic investigations on377</p> <p style="padding-left: 20px;">SAR-analysis of377</p>
--	--

2-Benzyl-1,1-diarylbut-2-ones	147	Carbamates side-chains	21
antiestrogenically active type	147	hydrogenolysis of	21
as estrogen receptor antagonist	147	in 1 β -carbapenem OCA-983 in biphasic media	21
biochemistry of	153	Cardiovascular diseases	13
chemistry of	148	development of gene therapies for	13
computational studies of	158	nucleic acid medicines in	13
cytotoxicity profile of	154	pyrrole imidazole poly amides (PY-IM) in	17
effect on apoptosis	157	ribozyme in	15
estrogen receptor binding studies of	154	role of antisense	14
estrogenic stimulation by	154	Cathepsin D inhibitors	27
inhibition of proliferation of human breast		characterization of	27
cancer MCF-7 cells by	153	preparation of	27
molecular modeling study of	147	with hydroxyethylamine isosteres	27
structure-activity relationships of	147	Cerium (III)/Neodymium(III) complexes	463
synthesis of	147	antioxidant activity of	467
Bioreductive drugs	315	as scavengers of X/XO-derived superoxide	
chemical entities developed as	315	radical	463
Bis-dihydropyridines	527	pharmacology of	466
structurally related to nifedipine	527	Chromene derivatives	363
vasodilator effects of	527	as azole antifungal target	363
Bis-dioxopiperazines	369	as lanosterol 14 α -demethylase inhibitor	363
anti-proliferative effects of	370	QSAR study on	363
Bisphosphonates	223	Compound prefiltering	102
caspase-3 activation assay of	224	Curcumin	169
cytotoxicity assay of	223	binds to CBP/p300 proteins	171
effect on proliferation of human ovarian cancer		to inhibit histone acetylation <i>in vivo</i>	170
cell lines	223	Cyclosporine-A	391
mechanism of	223	monitoring C ₀ (Trough)/C ₂ in	391
BPT	597	treatment of nephrotic syndrome	391
2-Bromoacridones	67	Cysteine derivatives	123
interact with P-glycoprotein by photolabeling	67	antiproliferative activity of	126
Caco-2 cell monolayer system	203	design/ligand docking of	123
Calcium channels	535	effect on melanoma cells	123
as therapeutic targets	536	solid phase synthesis of	126
auxiliary calcium channel subunits of	535	with antiproliferative activity	123
ω -conotoxin interaction with	538	Cystic fibrosis	499
design of small peptidic molecules targeting	541	adeno-associated virus vectors for	500
effect of morphine	537	adenovirus vector for	500
peptide inhibitors of	537	airway epithelium directed gene therapy for	499
small organic molecules targeting	539	gene delivery systems in	500
structure-activity relationship of ω -conotoxins		non-viral vectors for	501
AT	538	preclinical animal models of	502
Cancer	315	RNA virus vectors for	501
cytotoxin-releasing compounds in	320	DBPT	597
development of hypoxia selective cytotoxins		2'-Deoxyuridine	287
for	315	biological studies of	287
nitro compounds in	319	chemistry of	288
N-oxide derivatives in	315	<i>in vitro</i> anti-mycobacterial activities of	287
quinone derivatives in	319	synthesis of	287
Cannabinoid agonists	471	β -Diketonato complexes	227
A β [25-35]/(H ₂ O ₂)-induced apoptosis in		cellular DNA binding of	229
lymphocytes by	471	cellular sensitivity to	227
receptor-independent/P13K-dependent		MTT assay of	228
mechanisms of	471	of Chromium (III)	227

of Rhodium (III)	227	Histone hyperacetylation	127
of Ruthenium (III)	227	Homology modeling	191
Drug design	175	Hydroxamic acids	251
chimera method for	175	anti-inflammatory activity of	251
drug evolution concept in	175	as antioxidant	251
role of PABA chimera library	177	as novel lipoxygenase inhibitor	251
selection of scaffolds in	176	chemistry of	252
Duocarmycin C2	139	physicochemical studies of	254
biological evaluation of	139	synthetic methodology for	252
cytotoxicity studies of	144	Hypertensive renal diseases	15
(S)-(-)/R-(+)- <i>seco-iso</i> -cyclopropylfurano[e]		antisense treatments for	15
indoline-5,6,7-trimethoxyindole-2-carboxamide		ribozyme treatments for	17
(<i>iso</i> -CFI) analogs of	139	Insulin	299
synthesis of	139	to attenuates diabetes-related mitochondrial	
Europium (III)	439	alterations	299
chemistry of	440	Interleukin-2	265
complexes with appended DNA intercalators		autocrine production of	265
in	439	Interleukin-10	611
cytotoxic/pro-apoptotic activities of	439	in rat hepatic stellate cells	611
in human malignant cell lines	439	on expression of FAS/FALL	611
pharmacology of	440	Inter-organelle cross-talk	1
Experimental acute pancreatitis	423	ASK/MAPK kinases-dependent	3
in rats	423	between cytosol/mitochondria	2
whole blood chemiluminescence assay to		between endoplasmic reticulum/mitochondria	5
study	424	between nucleus/mitochondria	4
Factor Xa	349	modulation of	1
containing 4-amidinobenzylamide as P1		mutual compartment influence of	1
residue	349	to control apoptosis	1
substrate analogue inhibitors of	349	Iron chelators	133
FAMS complex	191	antimalarial activity of	133
Fibrinogen receptor antagonists	295	design of	133
Flavone derivatives	401	synthesis of	133
molecular interactions with human cytochrome		JNK MAP kinase	216
P450 1A2	401	inhibitors of	216
Folic acid	407	JWH-015	471
as Fenton-modulator	407	A β [25-35]/(H ₂ O ₂)-induced apoptosis in	
physiological implication of	407	lymphocytes by	471
Galectin-3 glycomimetic inhibitors	481	receptor-independent/P13K-dependent	
based on 3D docked structures	481	mechanisms of	471
binding affinity prediction of	487	Leu-enkephalin analogues	203
hydrophobicity (lipophilicity) of	487	enzymatic stability of	203
QSAR model for	481	lipid/sugar modified	203
Gene therapy	499	role of caco-2 cell	203
barriers to lung gene transfer in	499	route of absorption of	203
Glycolipid-arsenicals (III)	79	Matrix metalloproteinase (MMP)-7	523
anti-proliferative effects of	79	to activates MMP-8	523
effect on MCF-7 human breast cancer cells	79	Matrix metalloproteinase inhibitors	243
Hemorrhagic shock	271	hydroxamic acid analogs as	243
activation of pulmonary NF- κ B	271	quantitative structure-activity relationship	
AP-1 activation induced by	271	studies on	243
<i>via</i> heme oxygenase-1 induction	271		

Micro RNA expression	555	N-type calcium channel blockers	535
in murine embryonic stem cells	555	for treatment of pain	535
radiation-induced response of	555	Organochlorines	607
Mitogen activated protein (MAP) kinases	213	high concentrations of	607
c-Jun <i>N</i> -terminal kinase (JNK) based	214	in anorexia-cachexia syndrome	607
extracellular signal-regulated kinase (ERK)		in patient with kidney cancer	607
based	213	Oxicams	447
inhibitors for	215	COX selectivity of	447
signaling modules of	213	interactions of	447
MMP-13	523	with membrane bilayers	447
MMPT	597	Oxidative stress	425
Molecular modeling studies	309	within pancreatic tissue	425
against SARS	309	p53	471
of peptide drug candidates	309	p300 Histone acetyltransferase	169
MST-16	369	curcumin as inhibitor of	169
against a murine tumor model	370	p38 MAP kinase	214,215
anticancer effects of	369	inhibitors of	215
antitumor activity on LAX-83	371	PABA chimera library	178
medicinal chemistry of	369	Partially modified retro-inverse (PMRI) peptides	395
Multidrug resistant (MDR) cancer cells	63	as scaffolds for generating new molecular	
correlation between anti-calmodulin activity/		topology	395
anti-MDR activity	63	novel family of	395
correlation between anti-calmodulin activity/		Peptide vaccines	629
inhibition of cellular growth	70	advantages of	629
effect of vinblastine	63	clinical trials of	632
sensitization of	63	design of	629
<i>Mycobacterium avium</i>	505	MHC polymorphism in	632
antifolate inhibitorsfor	505	problems with	630
N-[4-1H(2H)-benzotriazol-1(2)-l)phenyl]		PGDF mimetics	295
alkylcarboxamides	577	<i>P</i> -glycoprotein	565
anti-viral activity of	577	computation calculations of	566
chemistry of	577	physicochemical characteristics of	565
<i>in vitro</i> evaluation of	577	<i>P</i> -glycoprotein inhibitors	565
molecular modeling of	579	computation calculations of	566
synthesis of	577	of cage dimeric 1,4-dihydropyridine type	565
virology of	579	physicochemical characteristics of	565
N ⁴ -(2,5-dimethylphenyl/-2-fluoro-5-methyl phenyl)		Phenazine 5,10-dioxide derivatives	511
semicarbazones	617	as hypoxic selective cytotoxins	511
anticonvulsant activity of	617	biological activity of	513
chemistry of	617	chemistry of	511
pharmacological activity of	618	DNA binding assay of	513
quantum mechanical modeling studies of	621	mechanism of action of	513
synthesis of	617	structure-activity relationship studies of	511,514
N ⁴ -(2,5-disubstituted phenyl) semicarbazones	617	3-Phenoxymethyl quinoxalin-2-ones	113
chemistry of	617	activity of	113
pharmacological activity of	618	biological assays of	115
quantum mechanical modeling of	617,621	chemistry of	119
Nephrotic syndrome	391	synthesis of	113
NF-κB	471	Pigment epithelium-derived factor (PEDF)	265
Non-ATP binding domains	217	effect on angiotensin II-induced T cell	
MAP kinase inhibition of	217	proliferation	265
NQO1	276		
assay of	276		
expression of	278		

effects on IL-2 mRNA levels	267	Sertraline	385
effects on NADPH oxidase activity in		determination of dissociation constant of	386
MOLT-3 T cells	267	determination of partition coefficient in	
effects on ROS generation in MOLT-3 T cells	267	cyclohexane/water system of	386
<i>p</i> -Nitrobenzyl esters	21	determination of partition coefficient in	
hydrogenolysis of	21	octanol/water system of	386
Poly(ADP-ribose) polymerase-1 inhibitor 3-		determination of thermodynamic solubility of	386
aminobenzamide	47	ionization of	385
effect on apoptosis induction by platinum		lipophilicity of	385
complexes	47	physico-chemical profiling of	385
in cisplatin-resistant tumor cells	47	solubility of	385
Probimane	369	Short synthetic peptides	627
against a murine tumor model	370	as vaccines	627
anticancer effects of	369	Small molecule kallikrein inhibitors	545
antitumor activity on LAX-83	371	binding kinetics studies of	546
medicinal chemistry of	369	discovery of highly potent type	545
Progressive renal disease	13	molecular modeling of	548
development of gene therapies for	13	plasma BK release studies of	547
nucleic acid medicines in	13	Sorbitol dehydrogenase (SDH)	239
pyrrole imidazole poly amides (PY-IM) in	17	expression of	240
role of antisense	14	inhibitory assay for	240
Protease inhibitor	349	purification of	240
anticoagulant activity of	357	4-(1,2,3,4-Tetrahydro-isoquinoline-7-yl) amino-4-	
x-ray crystallography of	350	oxo-butyric acid derivatives	295
Protein complex structures	191	Transcription factor Nrf2	275
automated homology modeling system for	191	Unliganded HIV-1 reverse transcriptase	491
molecular dynamics model of	491	molecular dynamics model of	491
QSAR	363	Vaccines	627
Quinoxalines	113	peptides as	628
activity of	113	Virtual screening	89,239
biological assays of	115	as analyzed by target class	89
chemistry of	119	consensus scoring in	107
synthesis of	113	discovery of sorbitol dehydrogenase inhibitors	
Radiation-induced alterations	557	from	239
of miRNA expression in ES	557	flexible receptor binding in	107
Resveratrol	275	of aspartyl proteases	100
in human K562 cells	275	of cysteine proteases	96
induction of quinone reductase NQO1 by	275	of G protein-coupled receptors	91
nuclear translocation of	275	of inhibitors to targets ATP binding site	93
Retinoic acids	431	of kinases	92
mechanism of action of	431	of metalloproteases	99
Retinoids	431	of nuclear hormone receptors	100
based therapies	436	of proteases	96
development of	436	of serine proteases	99
in clinical investigations	432	programs/databases in	90
in clinical use	431	to target structure	89
mechanism of action of	431	Xanthone	377
Ribozyme	15	cytoprotective effects of	377
principle of	15	from <i>Hypericum annulatum</i> in models of	
SARS	309	epirubicin-induced cytotoxicity	377
Septic shock	423	mechanistic investigations on	377
whole blood chemiluminescence assay to study ..	424	SAR-analysis of	377